- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02504554
Beneficial Bacteria Treatment for Autism (BBT)
Treating Gastrointestinal Problems in Children With Autism Using Beneficial Bacteria Treatment (BBT)
This is an open-label clinical trial to investigate a combination therapy for treating gastrointestinal problems in children with autism spectrum disorders.
The combination therapy includes beneficial bacteria.
Study Overview
Status
Detailed Description
This is an open-label clinical trial to evaluate the safety, tolerability, and feasibility of a combination therapy to treat gastrointestinal problems in children with autism spectrum disorders.
It involves a combination therapy including beneficial bacteria.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children ages 7-17 years
- Diagnosis of autism per Autism Diagnostic Interview-Revised (ADI-R)
- Moderate or Severe GI problems ( on the GSRS, a single score of 4 (severe) on any item, or a score of 3 (moderate) on two items, or a score of 2 (mild) or more on any 4 items
- No changes in medications, supplements, diet, therapies, or education in last 3 months, and no intention to change them during clinical trial
- General good physical health aside from gastrointestinal problems
- Cognitive Ability to Provide Informed Assent
Exclusion Criteria:
- Antibiotics in last 6 months
- Probiotics in last 3 months
- Single-gene disorder (Fragile X, etc.)
- Major brain malformation
- Tube feeding
- Severe gastrointestinal problems that require immediate treatment (life-threatening)
- Ulcerative Colitis, Crohn's Disease, diagnosed Celiac Disease, Eosinophilic Gastroenteritis, or similar conditions
- Severely underweight/malnourished
- Recent or scheduled surgeries
- Current participation in other clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oral Group
This group will receive all treatments orally.
The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
|
an antibiotic
a bowel cleanse
a stomach acid suppressan
human fecal material; processed, frozen, administered orally
|
EXPERIMENTAL: Rectal Group
This group will receive some treatments rectally and some orally.
The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
|
an antibiotic
a bowel cleanse
a stomach acid suppressan
human fecal material; processed, frozen; administered orally and rectally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastrointestinal Symptom Responsiveness Scale (GSRS)
Time Frame: Baseline and 10 weeks (end of treatment)
|
The GSRS is a measure of gastrointestinal symptoms.
It includes 15 questions, rated on a Likert scale of 1-7, from no symptoms to severe symptoms, respectively (i.e., higher is worse).
We report an average score for all 15 questions, so the possible range for the average score is also 1-7.
|
Baseline and 10 weeks (end of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parent Global Impressions-Revised (PGI-R)
Time Frame: Baseline and 10 weeks (end of treatment)
|
The PGI-R is a rating of change of 18 autism symptoms compared to baseline, with each symptom rated on a Likert scale from -3 (much worse) to zero (no change) to +3 (much better).
We report the average change of the 18 symptoms, so the possible range is from -3 to +3.
|
Baseline and 10 weeks (end of treatment)
|
Blood Safety Markers (Assessment of Blood Chemistry Panel and Complete Blood Count)
Time Frame: Baseline and 10 weeks (end of treatment)
|
Number of participants who had a clinically significant change in their blood safety markers (comprehensive metabolic panel including kidney/liver function and complete blood count with differential)
|
Baseline and 10 weeks (end of treatment)
|
Childhood Autism Rating Scale (CARS)
Time Frame: Baseline and 10 weeks (end of treatment)
|
The CARS is an assessment of 15 autism-related symptoms.
Each item is scored on a scale of 1 (no symptoms) to 4 (severe symptoms), and the scores for each symptom are summed to obtain a total score.
So, the possible scores range from 15 to 60, with a higher score indicating greater severity.
|
Baseline and 10 weeks (end of treatment)
|
Social Responsiveness Scale (SRS)
Time Frame: Baseline and 10 weeks (end of treatment)
|
The SRS is an assessment of social skills based on 65 items, where each item is scored on a range of 0 (no symptoms) to 3 (severe symptoms).
The total score is a sum of the individual scores, so the total possible range is from 0 to 195, with a higher score indicating greater severity of symptoms.
|
Baseline and 10 weeks (end of treatment)
|
Short Sensory Profile
Time Frame: baseline and 10 weeks
|
The Short Sensory Profile is an assessment of sensory problems. However, the data on this scale was not collected due to administrative error. |
baseline and 10 weeks
|
Vineland Adaptive Behavior Scale (VABS)
Time Frame: baseline and 18 weeks (8 weeks after treatment stopped)
|
The VABS is an assessment of adaptive behaviors, and we analyzed it to determine the developmental age of the participants, with possible scores ranging from 0 years to 21 years.
|
baseline and 18 weeks (8 weeks after treatment stopped)
|
Daily Stool Record (DSR)
Time Frame: Baseline and 10 weeks (end of treatment)
|
The DSR is a record of the type of stool that a participant had each day, using the Bristol Stool Form which ranges from 1 (very hard) to 7 (liquid).
We then analyzed the data as % days of abnormal stools over a 14 day period, where an abnormal stool is defined as an unusually hard stool (types 1-2), unusually soft stool (types 6-7), or no stool that day.
So, the possible range of % days of abnormal stools is from 0% to 100%, with a higher score indicating a more severe problem.
|
Baseline and 10 weeks (end of treatment)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Neurodevelopmental Disorders
- Child Development Disorders, Pervasive
- Autistic Disorder
- Autism Spectrum Disorder
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Vancomycin
- Omeprazole
Other Study ID Numbers
- STUDY00001053
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorders
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
Emory UniversityNational Institute of Mental Health (NIMH)Terminated
-
University of California, Los AngelesNational Institute of Mental Health (NIMH); Florida State University; Autism...CompletedAutism Spectrum DisordersUnited States
-
University Hospital, MontpellierCaisse Nationale de Solidarité pour l'AutonomieActive, not recruitingAutism Spectrum DisordersFrance
-
Institut National de la Santé Et de la Recherche...Completed
-
Linmarie SikichEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedAutism Spectrum DisordersUnited States
-
National Human Genome Research Institute (NHGRI)CompletedAutism Spectrum DisordersUnited States
-
University of California, San DiegoCompletedAutism Spectrum DisordersUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH)Completed
Clinical Trials on oral Vancomycin
-
St. Luke's Hospital, Chesterfield, MissouriCompletedClostridium Difficile Infection | Prophylaxis | Vancomycin
-
University of Wisconsin, MadisonNational Institute of Allergy and Infectious Diseases (NIAID)CompletedClostridium Difficile Infection RecurrenceUnited States
-
University of MinnesotaRecruitingPrimary Sclerosing CholangitisUnited States
-
University of Nevada, RenoRenown Regional Medical CenterCompletedClostridium Difficile InfectionUnited States
-
Vedanta Biosciences, Inc.RecruitingUlcerative Colitis | Colitis, UlcerativeUnited States, Netherlands, Lithuania, Bulgaria, Hungary, Ukraine, Czechia, Poland, United Kingdom
-
Medical College of WisconsinCompletedClostridium Difficile InfectionUnited States
-
University Hospital Birmingham NHS Foundation TrustRecruitingInflammatory Bowel Diseases | Primary Sclerosing CholangitisUnited Kingdom
-
Astellas Pharma Europe B.V.Merck Sharp & Dohme LLCCompletedClostridium Difficile-associated Diarrhea (CDAD)United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
-
University of South FloridaTerminatedClostridium Difficile Infection | Clostridium Difficile Infection RecurrenceUnited States
-
Vedanta Biosciences, Inc.Completed